Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

The commercial launch of Casgevy continues to gain momentum, with Vertex leading the charge. Meanwhile, CRISPR Therapeutics is working to advance several other gene-editing programs. The company's ...

More than a year after Vertex Pharmaceuticals and CRISPR Therapeutics won FDA approval for the world’s first CRISPR edited therapy Casgevy® (“exa-cel” or exagamglogene autotemcel ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other shorted stocks in 2025. Reuters reported that President Trump’s tariffs have ...

Both SCD and TDT indications have a significant unmet medical need. With Casgevy’s approval, CRISPR Therapeutics/Vertex offers a new treatment option to nearly 60,000 patients living with severe ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP ... Its lead product, Casgevy, was co-developed with Vertex Pharmaceuticals and has become the new standard of care for sickle ...

Both SCD and TDT indications have a significant unmet medical need. With Casgevy’s approval, CRISPR Therapeutics/Vertex offers a new treatment option to nearly 60,000 patients living with severe SCD ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...

US Bancorp DE lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 53.3% during the 4th quarter, Holdings Channel reports.The firm owned 1,209 shares of the ...